Lung stem cell infusion trial aims to halt scarring in IPF patients
NCT ID NCT04262167
First seen Feb 01, 2026 · Last updated May 15, 2026 · Updated 17 times
Summary
This early-phase trial tests whether a person's own lung stem cells, grown from a small biopsy and given through an IV, are safe for treating idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and breathing difficulty. About 24 adults aged 40-80 with IPF will receive either a low or high dose of stem cells or standard care alone. Researchers will monitor for side effects and changes in lung scarring over two years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS AND PROGRESSIVE FIBROTIC INTERSTITIAL LUNG DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of North Carolina as Chapel Hill
Chapel Hill, North Carolina, 27514, United States
Conditions
Explore the condition pages connected to this study.